Table 1 Baseline characteristics of the patients in this study
Variable | Training cohort (n = 117) | Test cohort (n = 50) | p-value |
|---|---|---|---|
CA199 (kU/L) | 7.85 (4.05, 17.86) | 8.76 (3.77, 17.63) | 0.760 |
CEA (ng/mL) | 4.43 (2.61, 10.41) | 3.40 (2.16, 8.10) | 0.259 |
Tumor length (mm) | 45.00 (34.50, 57.00) | 46.65 (36.75, 60.75) | 0.483 |
Maximal tumor thickness (mm) | 10.00 (8.00, 13.00) | 10 (7.00, 12.00) | 0.232 |
Age | 64.00 (55.00, 69.50) | 67.50 (56.75, 71.00) | 0.369 |
Sex | Â | Â | 0.375 |
 Male | 83 (70.21%) | 32 (72.73%) |  |
 Female | 34 (29.79%) | 18 (27.27%) |  |
Location | Â | Â | 0.521 |
 Upper | 23 (28.72%) | 13 (27.27%) |  |
 Middle | 60 (44.68%) | 26 (63.64%) |  |
 Lower | 34 (26.60%) | 11 (9.09%) |  |
cT stage | Â | Â | 0.557 |
 T1 | 1 (4.26%) | 1 (0.00%) |  |
 T2 | 21 (47.87%) | 6 (50.00%) |  |
 T3a/b | 41 (17.02%) | 21 (31.82%) |  |
 T4a | 54 (30.85%) | 22 (18.18%) |  |
pN stage | Â | Â | 0.206 |
 N0 | 39 (33.33%) | 21 (42%) |  |
 N1a | 18 (15.38%) | 11 (22%) |  |
 N1b | 33 (28.21%) | 14 (28%) |  |
 N2a | 19 (16.24%) | 3 (6%) |  |
 N2b | 8 (6.84%) | 1 (2%) |  |
Pathological LN | Â | Â | 0.285 |
 Negative | 39 (33.33%) | 21 (42%) |  |
 Positive | 78 (66.67%) | 29 (58%) |  |
Pathological ENE | Â | Â | 0.008 |
 Negative | 74 (63.3%) | 42 (84%) |  |
 Positive | 43 (36.7%) | 8 (16%) |  |
MRI-reported EMVI | Â | Â | 0.321 |
 Negative | 93 (69.15%) | 43 (77.27%) |  |
 Positive | 24 (30.85%) | 7 (22.73%) |  |
LN-irregular border and/or adjacent fat invasion | Â | Â | 0.990 |
 Negative | 75 (64.10%) | 32 (64.00%) |  |
 Positive | 42 (35.90%) | 18 (36.00%) |  |
LN-CSE | Â | Â | 0.985 |
 Absence | 63 (53.85%) | 27 (54.00%) |  |
 Existence | 54 (46.15%) | 23 (46.00%) |  |
LN-heterogeneous intensity | Â | Â | 0.598 |
 Negative | 77 (65.81%) | 35 (70.00%) |  |
 Positive | 40 (34.19%) | 15 (30.00%) |  |